Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress

NCT04382586 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04382586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04382586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2020
Completion date
February 1, 2021
Enrollment
63 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 pulmonary complications